H. Lundbeck A/S

LSE:0ABR Stock Report

Market Cap: DKK 40.9b

H. Lundbeck Valuation

Is 0ABR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0ABR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
DKK 157.06
Fair Value
77.6% undervalued intrinsic discount
11
Number of Analysts

Below Fair Value: 0ABR (DKK35.2) is trading below our estimate of fair value (DKK157.06)

Significantly Below Fair Value: 0ABR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0ABR?

Key metric: As 0ABR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0ABR. This is calculated by dividing 0ABR's market cap by their current earnings.
What is 0ABR's PE Ratio?
PE Ratio16x
EarningsDKK 2.69b
Market CapDKK 40.94b

Price to Earnings Ratio vs Peers

How does 0ABR's PE Ratio compare to its peers?

The above table shows the PE ratio for 0ABR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.4x
HIK Hikma Pharmaceuticals
22.1x11.0%UK£5.0b
GSK GSK
22.8x20.8%UK£57.1b
ANCR Animalcare Group
35.2xn/aUK£167.6m
AZN AstraZeneca
33.6x16.9%UK£174.2b
0ABR H. Lundbeck
16x9.3%DKK 40.9b

Price-To-Earnings vs Peers: 0ABR is good value based on its Price-To-Earnings Ratio (16x) compared to the peer average (28.4x).

Price to Earnings Ratio vs Industry

How does 0ABR's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0ABR 16.0xIndustry Avg. 22.1xNo. of Companies10PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0ABR is good value based on its Price-To-Earnings Ratio (16x) compared to the European Pharmaceuticals industry average (21.8x).

Price to Earnings Ratio vs Fair Ratio

What is 0ABR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0ABR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16x
Fair PE Ratio25.5x

Price-To-Earnings vs Fair Ratio: 0ABR is good value based on its Price-To-Earnings Ratio (16x) compared to the estimated Fair Price-To-Earnings Ratio (25.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Price Target
Consensus Narrative from 11 Analysts
DKK 42.29
Fair Value
16.8% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 09:16
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

H. Lundbeck A/S is covered by 40 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter AnkersenABG Sundal Collier
Kamla SinghAlphaValue
Charles PitmanBarclays